Strategic Development of Complex Oral Therapies
By Rebecca Coutts
November 2, 2026
Early characterization and manufacturing planning can help developers choose the right formulation strategy for complex oral therapies
5 min read
False
Advertisement
Formulation
Staying the Course: Sitting Down With Mike Cooke
By Henry Thomas, James Strachan
October 29, 2026
AmacaThera Co-Founder and CEO Mike Cooke reflects on the long road from academic discovery to a potential new treatment for post-operative pain
9 min read
Meeting the Demands of Injectable Drug Delivery
October 22, 2026
Stevanato Group’s Adam Stops discusses how delivery systems and manufacturing capabilities can keep pace with increasingly complex drug formulations
1 min read
The Confidentiality Barrier to AI-Enabled Drug Development
By Timothy Pas, Laure Descamps
July 27, 2026
AI can help formulation teams better predict performance and allocate resources, but proprietary data protections remain a critical bottleneck
3 min read
Why Drug Development Still Lacks Integration
July 21, 2026
John McDermott reflects on why early drug development remains fragmented – and how integrated approaches may shorten timelines
4 min read
In Vivo CAR T: A New Route to Treating Autoimmune Disease
By Ying K. Tam, Sean Semple
July 13, 2026
How targeted in vivo CAR T delivery could pave the way for autoimmune disease treatments
6 min read
Reformulating the Future of Small Molecules
June 30, 2026
A special collection of recent stories exploring oral dose innovation, API stability, nitrosamine testing, and the evolving science of small molecule medicines
1 min read
Navigating Formulation Change in the EU
By Matthew Weinberg
April 15, 2026
How to turn regulatory complexity into strategic strength
7 min read
Solving the Problem of Insolubility: Part III
March 3, 2026
Exploring new applications for KinetiSol and the evolving role of CDMOs in bringing the next generation of complex molecules to patients
4 min read
Solving the Problem of Insolubility: Part II
February 24, 2026
KinetiSol’s solvent-free mixing process turns “brick dust” drugs into stable amorphous dispersions
5 min read
